TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology

Company Overview - Tandem Diabetes Care, Inc. (TNDM) has launched Control-IQ+ technology, an advanced hybrid closed-loop algorithm for diabetes management, compatible with t:slim X2 insulin pump and Tandem Mobi System, targeting individuals with type 1 diabetes aged 2 and older, as well as adults with type 2 diabetes [1][3] Product Features - Control-IQ+ builds on the existing Control-IQ algorithm, allowing users to program extended boluses for up to 8 hours to manage delayed glucose rises [5] - New features include expanded weight parameters (20-440 lbs) and total daily insulin (5-200 units) to accommodate diverse insulin needs, along with Temp Basal Rate adjustments for short-term glucose management [6] Market Performance - Following the announcement of Control-IQ+, TNDM shares increased by 1.1% in after-market trading [2] - TNDM currently has a market capitalization of $1.33 billion and is projected to have an earnings per share (EPS) growth rate of 38.7$16.43 billion in 2023, with an expected compound annual growth rate of 7.9% by 2027, driven by the rising prevalence of diabetes and demand for advanced solutions [8][9] Strategic Developments - Tandem Diabetes has signed a multi-year collaboration with the University of Virginia Center for Diabetes Technology to advance research on fully automated closed-loop insulin delivery systems [11] - The t:slim X2 insulin pump became fully compatible with Dexcom G7 and G6 Continuous Glucose Monitoring Systems in December 2024 [11] Stock Performance - Over the past year, TNDM shares have declined by 38.2%, contrasting with the industry decline of 7.5% [12]